Harris A Gelbard

List of Publications by Year
in descending order

119 papers	6,980 citations	47 h-index	80 g-index
		47006	62596
126 all docs	126 docs citations	126 times ranked	8242 citing authors

#	Article	IF	Citations
1	Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. BioTechniques, 2011, 50, 98-115.	1.8	924
2	Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. Journal of Neuroimmunology, 1999, 98, 185-200.	2.3	299
3	Tumor Necrosis Factor Î± Inhibits Glutamate Uptake by Primary Human Astrocytes. Journal of Biological Chemistry, 1996, 271, 15303-15306.	3.4	291
4	Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. Neuron, 2004, 41, 563-572.	8.1	243
5	Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology, 2003, 312, 60-73.	2.4	194
6	Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System. Journal of Immunology, 2000, 164, 1333-1339.	0.8	186
7	HIV-1 Tat Induces Neuronal Death via Tumor Necrosis Factor-Î± and Activation of Non-N-methyl-d-aspartate Receptors by a NFÎºB-Independent Mechanism. Journal of Biological Chemistry, 1998, 273, 17852-17858.	3.4	171
8	Neurotoxic Effects of Tumor Necrosis Factor Alpha in Primary Human Neuronal Cultures are Mediated by Activation of the Glutamate AMPA Receptor Subtype: Implications for AIDS Neuropathogenesis. Developmental Neuroscience, 1993, 15, 417-422.	2.0	165
9	HIV-1 Tat-Mediated Activation of Glycogen Synthase Kinase-3Î² Contributes to Tat-Mediated Neurotoxicity. Journal of Neurochemistry, 2002, 73, 578-586.	3.9	162
10	Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. Journal of NeuroVirology, 1997, 3, 168-173.	2.1	150
11	Two-Photon NADH Imaging Exposes Boundaries of Oxygen Diffusion in Cortical Vascular Supply Regions. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 68-81.	4.3	141
12	Postnatal development of dopamine D1 and D2 receptor sites in rat striatum. Developmental Brain Research, 1989, 49, 123-130.	1.7	128
13	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	2.2	121
14	Platelet-activating Factor Receptor Activation. Journal of Biological Chemistry, 1998, 273, 17660-17664.	3.4	114
15	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2003, 23, 9162-9170.	3.6	113
16	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. Journal of Neuroscience, 2011, 31, 3148-3157.	3.6	110
17	Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: Potential role in neuropathogenesis. Journal of NeuroVirology, 2004, 10, 25-32.	2.1	102
18	Tumor Necrosis Factor-Alpha in Normal and Diseased Brain: Conflicting Effects Via Intraneuronal Receptor Crosstalk?. Journal of NeuroVirology, 2002, 8, 611-624.	2.1	98

#	Article	IF	Citations
19	HIV-1 Tat Activates Neuronal Ryanodine Receptors with Rapid Induction of the Unfolded Protein Response and Mitochondrial Hyperpolarization. PLoS ONE, 2008, 3, e3731.	2.5	96
20	HIV-1 Transactivator of Transcription Protein Induces Mitochondrial Hyperpolarization and Synaptic Stress Leading to Apoptosis. Journal of Immunology, 2005, 174, 4333-4344.	0.8	95
21	Lithium therapy for human immunodeficiency virus type 1â€“associated neurocognitive impairment. Journal of NeuroVirology, 2009, 15, 176-186.	2.1	90
22	Developmental Differences in Acute Nigrostriatal and Mesocorticolimbic System Response to Haloperidol. Neuropsychopharmacology, 1993, 9, 147-156.	5.4	86
23	Activation of glycogen synthase kinase 3 beta (GSK-3Î²) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. European Journal of Neuroscience, 2001, 13, 1913-1922.	2.6	85
24	Comparison of Cell Cycle Arrest, Transactivation, and Apoptosis Induced by the Simian Immunodeficiency Virus SIVagm and Human Immunodeficiency Virus Type 1 vpr Genes. Journal of Virology, 2001, 75, 3791-3801.	3.4	85
25	HIV-1 infection of the developing nervous system: central role of astrocytes in pathogenesis. Virus Research, 1994, 32, 253-267.	2.2	84
26	HIV-1-induced neuronal injury in the developing brain. Journal of Leukocyte Biology, 1999, 65, 453-457.	3.3	82
27	Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-ÎºB (NF-ÎºB)-dependent mechanism. Journal of Neurochemistry, 2001, 78, 874-889.	3.9	81
28	Functional Synergy between CD40 Ligand and HIV-1 Tat Contributes to Inflammation: Implications in HIV Type 1 Dementia. Journal of Immunology, 2007, 178, 3226-3236.	0.8	79
29	HIV-1 Trans Activator of Transcription Protein Elicits Mitochondrial Hyperpolarization and Respiratory Deficit, with Dysregulation of Complex IV and Nicotinamide Adenine Dinucleotide Homeostasis in Cortical Neurons. Journal of Immunology, 2007, 178, 869-876.	0.8	78
30	LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. Journal of Neuroinflammation, 2012, 9, 261.	7.2	77
31	Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain, Behavior, and Immunity, 2020, 87, 739-750.	4.1	77
32	Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia. Alzheimer's and Dementia, 2020, 16, 734-749.	0.8	73
33	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2005, 25, 8375-8385.	3.6	72
34	Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. Journal of Clinical Investigation, 2005, 115, 3185-3192.	8.2	72
35	Antioxidants are required during the early critical period, but not later, for neuronal survival. Journal of Neuroscience Research, 2004, 78, 485-492.	2.9	69
36	Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3. Journal of Medicinal Chemistry, 2013, 56, 8032-8048.	6.4	69

#	Article	IF	Citations
37	Simultaneous In Situ Detection of Apoptosis and Necrosis in Monolayer Cultures by TUNEL and Trypan Blue Staining. BioTechniques, 1997, 22, 1102-1106.	1.8	66
38	The New Small-Molecule Mixed-Lineage Kinase 3 Inhibitor URMC-099 Is Neuroprotective and Anti-Inflammatory in Models of Human Immunodeficiency Virus-Associated Neurocognitive Disorders. Journal of Neuroscience, 2013, 33, 9998-10010.	3.6	65
39	HIV-1 Tat-Induced Microgliosis and Synaptic Damage via Interactions between Peripheral and Central Myeloid Cells. PLoS ONE, 2011, 6, e23915.	2.5	63
40	Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults. Antimicrobial Agents and Chemotherapy, 2004, 48, 4328-4331.	3.2	59
41	A Thin-skull Window Technique for Chronic Two-photon In vivo Imaging of Murine Microglia in Models of Neuroinflammation. Journal of Visualized Experiments, 2010, , .	0.3	56
42	Human Immunodeficiency Virus-1 Tat Activates Calpain Proteases via the Ryanodine Receptor to Enhance Surface Dopamine Transporter Levels and Increase Transporter-Specific Uptake and Vmax. Journal of Neuroscience, 2010, 30, 14153-14164.	3.6	54
43	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Molecular Neurodegeneration, 2014, 9, 58.	10.8	52
44	Dopamine D1 receptor development depends on endogenous dopamine. Developmental Brain Research, 1990, 56, 137-140.	1.7	50
45	Inhibition of Mixed Lineage Kinase 3 Prevents HIV-1 Tat-Mediated Neurotoxicity and Monocyte Activation. Journal of Immunology, 2006, 177, 702-711.	0.8	50
46	Leucine-Rich Repeat Kinase 2 Modulates Neuroinflammation and Neurotoxicity in Models of Human Immunodeficiency Virus 1-Associated Neurocognitive Disorders. Journal of Neuroscience, 2015, 35, 5271-5283.	3.6	50
47	In Situ Trypan Blue Staining of Monolayer Cell Cultures for Permanent Fixation and Mounting. BioTechniques, 1997, 22, 1020-1024.	1.8	49
48	Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. Journal of Virology, 2014, 88, 9504-9513.	3.4	48
49	Neuroprotective Activities of CEP-1347 in Models of NeuroAIDS. Journal of Immunology, 2010, 184, 746-756.	0.8	47
50	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. Journal of Clinical Investigation, 2017, 127, 857-873.	8.2	44
51	Neuropathogenesis of AIDS. Trends in Molecular Medicine, 1996, 2, 16-23.	2.6	43
52	Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3Î² to antagonize nuclear factor-ÎºB survival pathway in neurons. European Journal of Neuroscience, 2006, 23, 2623-2634.	2.6	43
53	The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. Journal of NeuroVirology, 1996, 2, 111-117.	2.1	39
54	Glycogen Synthase Kinase 3 Beta (GSK-3Î²) as a Therapeutic Target in NeuroAIDS. Journal of NeuroImmune Pharmacology, 2007, 2, 93-96.	4.1	39

#	Article	IF	Citations
55	Functional Interplay Between Nuclear Factor-Î°B and c-Jun Integrated by Coactivator p300 Determines the Survival of Nerve Growth Factor-Dependent PC12 Cells. Journal of Neurochemistry, 2001, 74, 527-539.	3.9	38
56	Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis. Journal of Neuroscience, 2016, 36, 1336-1346.	3.6	38
57	Dopamine D1 autoreceptor function: possible expression in developing rat prefrontal cortex and striatum. Developmental Brain Research, 1991, 63, 229-235.	1.7	36
58	URMC-099 facilitates amyloid-Î² clearance in a murine model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 137.	7.2	36
59	HIV-1-associated dementia: a basic science and clinical perspective. Aids Reader, 2002, 12, 358-68.	0.3	34
60	Protecting the Synapse: Evidence for a Rational Strategy to Treat HIV-1 Associated Neurologic Disease. Journal of NeuroImmune Pharmacology, 2006, 1, 20-31.	4.1	30
61	Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis. JCI Insight, 2017, 2, .	5.0	30
62	Neuroprotective strategies for HIV-1 associated dementia. Neurotoxicity Research, 2004, 6, 503-521.	2.7	29
63	Ultrastructure of microglia-synapse interactions in the HIV-1 Tat-injected murine central nervous system. Communicative and Integrative Biology, 2013, 6, e27670.	1.4	27
64	The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 109-122.	3.3	27
65	The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders. Journal of Neuroinflammation, 2019, 16, 193.	7.2	25
66	Proteasome blockers inhibit TNF-Î± release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. Journal of Neuroimmunology, 1999, 95, 55-64.	2.3	24
67	Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. Annals of Neurology, 2000, 48, 590-602.	5.3	24
68	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Journal of Neuroimmunology, 2009, 213, 47-59.	2.3	24
69	Apoptosis in development and disease of the nervous system: II. Apoptosis in childhood neurologic disease. Pediatric Neurology, 1997, 16, 93-97.	2.1	22
70	The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-Î² degradation. Journal of Neuroinflammation, 2016, 13, 184.	7.2	22
71	Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs. Neuron, 2020, 108, 784-796.e3.	8.1	22
72	MLK3 regulates fMLP-stimulated neutrophil motility. Molecular Immunology, 2014, 58, 214-222.	2.2	21

#	Article	IF	Citations
73	Adjunctive therapies for HIV-1 associated neurologic disease. Neurotoxicity Research, 2005, 8, 161-166.	2.7	20
74	Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation. Frontiers in Cellular Neuroscience, 2015, 9, 505.	3.7	20
75	Allotransplanted Neurons Used to Repair Peripheral Nerve Injury Do Not Elicit Overt Immunogenicity. PLoS ONE, 2012, 7, e31675.	2.5	19
76	Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture. Journal of NeuroVirology, 2004, 10, 400-408.	2.1	18
77	Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2008, 52, 3035-3039.	3.2	18
78	The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases. Frontiers in Immunology, 2021, 12, 607641.	4.8	18
79	Activation of adenosine A2A receptor protects sympathetic neurons against nerve growth factor withdrawal. Journal of Neuroscience Research, 2004, 77, 258-269.	2.9	17
80	The Phospholipid Mediator Platelet-Activating Factor Mediates Striatal Synaptic Facilitation. Journal of NeuroImmune Pharmacology, 2007, 2, 194-201.	4.1	15
81	Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Current Opinion in HIV and AIDS, 2014, 9, 585-590.	3.8	15
82	The Mixed-Lineage Kinase Inhibitor URMC-099 Protects Hippocampal Synapses in Experimental Autoimmune Encephalomyelitis. ENeuro, 2018, 5, ENEURO.0245-18.2018.	1.9	15
83	Matters of size: Roles of hyaluronan in CNS aging and disease. Ageing Research Reviews, 2021, 72, 101485.	10.9	15
84	Neuroprotective Strategies for HIV-1-Associated Neurologic Disease. Annals of the New York Academy of Sciences, 1999, 890, 312-313.	3.8	14
85	Immunohistochemical Assessment of Fractalkine, Inflammatory Cells, and Human Herpesvirus 7 in Human Salivary Glands. Journal of Histochemistry and Cytochemistry, 2004, 52, 671-681.	2.5	14
86	Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. Journal of NeuroVirology, 2013, 19, 254-260.	2.1	14
87	HIV Tat causes synapse loss in a mouse model of HIVâ€associated neurocognitive disorder that is independent of the classical complement cascade component C1q. Glia, 2018, 66, 2563-2574.	4.9	13
88	Quantum Dots for Improved Single-Molecule Localization Microscopy. Journal of Physical Chemistry B, 2021, 125, 2566-2576.	2.6	12
89	Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. Neurotherapeutics, 2010, 7, 392-398.	4.4	11
90	Near-field Quantification of Complement Receptor 1 (CR1/CD35) Protein Clustering in Human Erythrocytes. Journal of NeuroImmune Pharmacology, 2012, 7, 539-543.	4.1	10

#	Article	IF	Citations
91	Pharmacologic Inhibition of MLK3 Kinase Activity Blocks the In Vitro Migratory Capacity of Breast Cancer Cells but Has No Effect on Breast Cancer Brain Metastasis in a Mouse Xenograft Model. PLoS ONE, 2014, 9, e108487.	2.5	9
92	Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine, 2018, 13, 2139-2154.	3.3	9
93	The Neuropathogenesis of HIV-1 Infection. , 2004, , 95-115.		8
94	Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure. Hearing Research, 2010, 270, 21-27.	2.0	8
95	The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss. Experimental Neurology, 2019, 318, 157-164.	4.1	7
96	Synapses and Sisyphus: life without paraplegin. Journal of Clinical Investigation, 2004, 113, 185-187.	8.2	7
97	Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption. Journal of Neuroscience Methods, 1998, 83, 159-164.	2.5	6
98	Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats. Neuroscience Letters, 1998, 247, 99-102.	2.1	6
99	Directional histogram ratio at random probes: A local thresholding criterion for capillary images. Pattern Recognition, 2013, 46, 1933-1948.	8.1	6
100	Allotransplanted DRG neurons or Schwann cells affect functional recovery in a rodent model of sciatic nerve injury. Neurological Research, 2014, 36, 1020-1027.	1.3	6
101	Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. Journal of NeuroImmune Pharmacology, 2019, 14, 44-51.	4.1	6
102	Clinical characteristics and outcomes after newâ€onset seizure among Zambian children with HIV during the antiretroviral therapy era. Epilepsia Open, 2022, 7, 315-324.	2.4	5
103	URMCâ€099 prophylaxis prevents hippocampal vascular vulnerability and synaptic damage in an orthopedic model of delirium superimposed on dementia. FASEB Journal, 2022, 36, e22343.	0.5	5
104	Characteristics of [3H]1Î±, 25-(OH)2D3 binding to nuclear fractions from rat pituitary adenoma GH3 cells. Life Sciences, 1981, 29, 1051-1056.	4.3	4
105	The darker side of varicella zoster infection. Neurology, 2020, 94, 193-194.	1.1	4
106	Lipids and cognition make good bedfellows for neuroAIDS. Neurology, 2013, 81, 1480-1481.	1.1	2
107	Neuroimmune Pharmacology, 2nd Edition â€“ A Perspective. Journal of NeuroImmune Pharmacology, 2017, 12, 211-212.	4.1	1
108	Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia. Epilepsia, 2020, 61, 2705-2711.	5.1	1

#	Article	IF	Citations
109	This Is Your Brain on (Low) Glucose. Trends in Neurosciences, 2020, 43, 933-935.	8.6	1
110	Release of the neuronal glycoprotein ICAMâ€5 in serum after hypoxicâ€ischemic injury. Annals of Neurology, 2000, 48, 590-602.	5.3	1
111	HIV-1-Derived Neurotoxic Factors: Effects on Human Neuronal Cultures. , 1995, , 61-71.		1
112	The Cell Culture Environment Regulates the Transcription Factor MafB in BV-2 Microglia. Matters, 2021, 2021, .	1.0	1
113	Elucidating the neuropathophysiology of COVID-19 using quantum dot biomimetics of SARS-CoV-2. , 2022, , .		1
114	Capillary extraction by detecting polarity in circular profiles. IET Image Processing, 2016, 10, 339-348.	2.5	0
115	Neuroimmunology and the Pathogenesis of HIV-1 Encephalitis in the HAART Era: Implications for Neuroprotective Treatment. , 0, , 137-149.		0
116	Human Immunodeficiency Virus Type 1 Infection. Frontiers in Neuroscience, 1998, , .	0.0	0
117	HIV-1 Infection of the CNS. , 1999, , 511-519.		0
118	HAND Adjunctive Therapies: Reversing Neuronal Injury. , 2015, , 1-6.		0
119	HAND Adjunctive Therapies: Reversing Neuronal Injury. , 2018, , 599-604.		0